Exenatide is an injectable drug in the new class of incretin mimetics, PBS listed from 1 August 2010 for type 2 diabetes. The listing is for combination therapy as either:
  • dual therapy, with metformin or a sulfonylurea, where HbA1c exceeds 7% and the patient cannot take these drugs together, or
  • triple therapy, with metformin and a sulfonylurea, where HbA1c exceeds 7% despite maximally tolerated doses of both drugs.
An in-depth NPS RADAR review of exenatide will be published online before our December print issue. To receive the exenatide review as soon as it is available, subscribe to the NPS RADAR email alert.